Lilly prevails in Alimta patent challenge

An Indiana district court has ruled in favor of Eli Lilly (LLY -0.4%) in a patent infringement case related to lung cancer med Alimta (pemetrexed). Would-be generic competitor Apotex will be prohibited from launching its alternative version until the patent expires in May 2020.

Apotex will likely appeal the decision.

https://seekingalpha.com/news/3528796-lilly-prevails-in-alimta-patent-challenge